Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti–complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether suc...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Noris, Marina, Galbusera, Miriam, Gastoldi, Sara, Macor, Paolo, Banterla, Federica, Bresin, Elena, Tripodo, Claudio, Bettoni, Serena, Donadelli, Roberta, Valoti, Elisabetta, Tedesco, Francesco, Amore, Alessandro, Coppo, Rosanna, Ruggenenti, Piero, Gotti, Eliana, Remuzzi, Giuseppe
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2014
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4162105/
https://ncbi.nlm.nih.gov/pubmed/25037630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-558296
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires